Search through all our worldwide HIV and AIDS news and features, using the topics below to filter your results by subjects including HIV treatment, transmission and prevention, and hepatitis and TB co-infections.

Pharmaceutical industry news

Show

From To
Gilead wins reversal of $2.54 bln hepatitis C drug patent verdict

A federal judge in Delaware has overturned a jury's verdict requiring Gilead Sciences Inc to pay a record $2.54 billion because its hepatitis C drugs Sovaldi and Harvoni infringed a patent held by rival Merck & Co Inc.

Published
19 February 2018
From
Nasdaq
ViiV Healthcare launches eighth phase III study in two-drug regimen programme for HIV-1 treatment

Today ViiV Healthcare, the global specialist HIV company majority owned by GSK, with Pfizer Inc. and Shionogi Limited as shareholders, announced the start of a phase III study designed to establish if adults with HIV-1 with current virologic suppression on a tenofovir alafenamide fumarate (TAF)-based regimen of at least three drugs are able to maintain viral suppression upon switching to a two-drug regimen (2DR) of dolutegravir (TIVICAY) and lamivudine (EPIVIR).

Published
08 February 2018
From
ViiV press release
US FDA approves Gilead triple HIV drug, rival files lawsuit

The U.S. Food and Drug Administration on Wednesday approved Biktarvy, Gilead Sciences Inc’s once-daily, triple-combination tablet for treatment of HIV infection, paving the way for the biotech company to capture more of the multibillion-dollar HIV drug market.

Published
08 February 2018
From
Reuters
Janssen HIV Drug U.K. Patent Extension Case to Go to EU Top Court

Sandoz Ltd.’s lawsuit to clear the way for its generic version of the Prezista HIV drug will now go to the Court of Justice of the European Union. The trial court sided with Janssen, saying that the SPC covered Prezista.

Published
07 February 2018
From
Bloomberg
Activists Demand Gilead Rescind nPEP Patient Access Program's Once-Per-Lifetime Use Limit

Gilead Sciences is coming under fire from HIV/AIDS activist groups for a recent change to its patient assistance program (PAP), which has imposed a once-per-lifetime limit on access to Truvada (tenofovir/FTC) as part of non-occupational post-exposure prophylaxis (nPEP). While the company will undertake "hardship reviews" for subsequent prescriptions, the activists say the process is unclear and will create a significant barrier to access, especially since nPEP should be started within 72 hours of possible exposure to HIV.

Published
02 February 2018
From
The Body
GlaxoSmithKline Projects Tough Environment for Triumeq and Tivicay

GlaxoSmithKline is witnessing increased demand for Tivicay as compared to Triumeq. Approximately 40% to 45% of the prescribed Tivicay is used by physicians with Gilead Sciences’ Tenofovir alafenamide (or TAF) therapy, Descovy. The company expects increased competition for its dolutegravir franchise after the launch of Gilead Sciences’ (GILD) integrase inhibitor, bictegravir.

Published
01 February 2018
From
Market Realist
NHS England seeks drug price cuts to eliminate hepatitis C by 2025

NHS England announced this week that it aims to eliminate hepatitis C by 2025 – if it can negotiate 'best value for money' deals with the pharmaceutical

Published
30 January 2018
By
Keith Alcorn
Brexit could leave patients unable to access new drugs

NHS may only get newly developed medicines a year after other EU countries, report warns.

Published
30 January 2018
From
The Guardian
Teva Announces Exclusive Launch of a Generic Version of Reyataz® in the United States

Reyataz® had annual sales of approximately $402 million in the U.S., according to IMS data as of October 2017.

Published
10 January 2018
From
Teva press release
Brexit: Fears of disruption to flow of medicines means UK must stay under EU regulation, say government figures

Looming disruption to the flow of medicines after Brexit means Britain must seek to stay under EU regulation, senior Government figures have conceded.

Published
09 January 2018
From
The Independent
← First12345...102Next →

Filter by country

Community Consensus Statement on Access to HIV Treatment and its Use for Prevention

Together, we can make it happen

We can end HIV soon if people have equal access to HIV drugs as treatment and as PrEP, and have free choice over whether to take them.

Launched today, the Community Consensus Statement is a basic set of principles aimed at making sure that happens.

The Community Consensus Statement is a joint initiative of AVAC, EATG, MSMGF, GNP+, HIV i-Base, the International HIV/AIDS Alliance, ITPC and NAM/aidsmap
close

This content was checked for accuracy at the time it was written. It may have been superseded by more recent developments. NAM recommends checking whether this is the most current information when making decisions that may affect your health.

NAM’s information is intended to support, rather than replace, consultation with a healthcare professional. Talk to your doctor or another member of your healthcare team for advice tailored to your situation.